ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Sakar Healthcare Limited appointed M/s. Kashyap R. Mehta & Partners as the company's Secretarial Auditors for a five-year term, effective September 22, 2026, following shareholder approval at the AGM.
Sakar Healthcare's 22nd AGM was held on September 22, 2026, adopting audited financials and re-appointing a director. Routine resolutions were passed including secretarial auditor appointment.
Sakar Healthcare Limited received 14 oncology product approvals in the EU, UK, and Canada. These approvals for licensed-out products and site variations will drive top-line sales growth.
Sakar Healthcare Limited submitted its 22nd Annual General Meeting notice and the Annual Report for FY 2025-26. The meeting is scheduled for September 22, 2026.
Sakar Healthcare Q1 FY27 results show strong oncology pivot with 38% YoY revenue growth and 120% profit jump.
Sakar Healthcare reported strong Q1FY27 consolidated results with 38% Revenue growth and 120% PAT growth, driven by its vertically integrated oncology business and expansion into regulated markets.
Sakar Healthcare announced Q1FY27 results, reporting 38% YoY revenue growth. Strong operating performance was driven by oncology product contracts and global dossier approvals.
Sakar Healthcare Ltd reported revenue from operations of ₹73 Cr (+38.5% YoY) and net profit of ₹10.3 Cr (+119.1% YoY) for Q1 FY27.
Sakar Healthcare Limited has scheduled a board meeting for 24th July 2026 to consider and approve the unaudited financial results for the quarter ended 30th June 2026.
Cobra India (Mauritius) Limited, a non-promoter entity, sold 4,89,026 shares of Sakar Healthcare via the open market. Its stake decreased from 6.45% to 4.40%.